ACE2 and COVID-19: ACE2 is less in the female kidney because of the effects of the ovary, and presence of estradiol (E2), and opens an area of therapeutic possibility to target ACE2.42 Balancing ACE2 may improve the outcome of COVID-19 in both sexes by reducing inflammation, thrombosis, and death.43 Thus research on ACE2 has significant value in overall management of COVID-19.